What monitoring criteria is associated with Amphotericin B?

What monitoring criteria is associated with Amphotericin B?

• A. No monitoring required
• B. Blood urea nitrogen (BUN) and creatinine at baseline
• C. Only liver function tests
• D. Daily weight checks

Answer: (B)

Amphotericin B is an antifungal medication that, while effective, can have significant nephrotoxic effects. Therefore, monitoring renal function is crucial for patients receiving this medication. Blood urea nitrogen (BUN) and creatinine levels are key indicators of kidney function, and obtaining baseline values is important in order to compare with subsequent measurements during treatment. This helps in identifying any potential deterioration in kidney function as the therapy progresses, allowing for timely adjustments to treatment or supportive care if needed. Monitoring for hepatotoxicity via liver function tests is important in some contexts, but it is not the primary concern specifically associated with Amphotericin B. Weight checks may be relevant in assessing overall health status or fluid retention but are not a specific monitoring requirement for this drug. Therefore, monitoring BUN and creatinine is the most appropriate practice to ensure patient safety during Amphotericin B therapy.

Amphotericin B is an antifungal medication that, while effective, can have significant nephrotoxic effects. Therefore, monitoring renal function is crucial for patients receiving this medication. Blood urea nitrogen (BUN) and creatinine levels are key indicators of kidney function, and obtaining baseline values is important in order to compare with subsequent measurements during treatment. This helps in identifying any potential deterioration in kidney function as the therapy progresses, allowing for timely adjustments to treatment or supportive care if needed.

Monitoring for hepatotoxicity via liver function tests is important in some contexts, but it is not the primary concern specifically associated with Amphotericin B. Weight checks may be relevant in assessing overall health status or fluid retention but are not a specific monitoring requirement for this drug. Therefore, monitoring BUN and creatinine is the most appropriate practice to ensure patient safety during Amphotericin B therapy.